GLP-1T:

Dosage, Benefits,

and Research Explained

GLP-1T is a groundbreaking dual-acting peptide therapy that targets both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This dual mechanism enhances blood sugar control, promotes weight loss, and improves metabolic health. 

GLP-1 Analogue 

CAS Number: 2023788-19-2

Formula: C22H438N48O68

Purchase from our preferred vendor: Project Zero

Purpose Dosage Frequency
Type 2 Diabetes 2.5 mg weekly
5-10 mg weekly
15 mg weekly
Once weekly
Weight Loss 2.5 mg weekly
5-10 mg weekly
15 mg weekly
Once weekly

How It Works

GLP-1T mimics two incretin hormones, GIP and GLP-1, which:

  • Improve insulin secretion and glucose control
  • Reduce appetite and food intake
  • Slow gastric emptying, promoting fullness

This dual mechanism makes it more effective than standard GLP-1 agonists like semaglutide (Ozempic, Wegovy).


 

Clinical Benefits

Blood Sugar Control

  • Lowers HbA1c by up to 2.24% in clinical trials
  • Improves fasting glucose and insulin sensitivity

Weight Loss

  • Clinical trials show up to 22.5% body weight loss
  • In the SURMOUNT-1 trial, 36% of participants lost 25%+ of body weight

Cardiometabolic Benefits

  • Lowers blood pressure and cholesterol
  • Improves lipid profiles and fasting insulin levels

Prediabetes Reversal

  • In 72 weeks, 95% of prediabetic participants returned to normal blood sugar levels

Comparison to Other Peptides

  • More effective than semaglutide (Ozempic, Wegovy) and dulaglutide (Trulicity) in both weight loss and glucose control
 

 

Dosage & Administration

  • Starting dose: 2.5 mg once weekly
  • Maintenance dose: Increased gradually up to 15 mg
  • Administration: Subcutaneous injection, once per week, with or without food

Always follow medical guidance when adjusting dosage.


 

Where to Buy GLP-1T

Looking for high-quality GLP-1T for research purposes? Purchase from our preferred vendor: Click Here to Buy GLP-1T


 

Ongoing Research

  • Cardiovascular Studies: Investigating long-term heart health benefits
  • New Applications: Potential treatments for NASH and obesity-related heart failure
  • Combination Therapies: Exploring synergy with other metabolic treatments
  • Long-Term Safety: Ongoing trials to evaluate extended use
 
Is GLP-1T FDA-approved?

Yes, for type 2 diabetes and weight management.

Blood sugar improvements appear within weeks. Weight loss progresses over months.

GLP-1T shows stronger results in both blood sugar control and weight loss.

Common side effects include nausea, digestive discomfort, and appetite reduction.

Referenced Citations

  1. Jastreboff, A.M., et al. (2023). Triple–Hormone-Receptor Agonist Retatrutide for Obesity. New England Journal of Medicine. [Online].
    Available: https://www.nejm.org/doi/full/10.1056/NEJMoa2301972
  2. Drugs.com. (2024). GLP-2: Uses, Dosage, Side Effects & Warnings. [Online].
    Available: https://www.drugs.com/tirzepatide.html
  3. Chavda, V.P., et al. (2022). GLP-2, a New Era of Dual-Targeted Treatment for Diabetes and Obesity: A Mini-Review. Frontiers in Pharmacology. [Online].
    Available: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9268041/
  4. DrugBank. (2024). GLP-2: Uses, Interactions, Mechanism of Action. [Online].
    Available: https://go.drugbank.com/drugs/DB15171
  5. Jastreboff, A.M., et al. (2022). GLP-2 Once Weekly for the Treatment of Obesity. New England Journal of Medicine. [Online].
    Available: https://www.nejm.org/doi/full/10.1056/NEJMoa2206038
  6. ChemicalBook. (2024). GLP-2 | 2023788-19-2. [Online].
    Available: https://www.chemicalbook.com/ChemicalProductProperty_EN_CB24869395.htm
Scroll to Top